Tamoxifen citrate
Catalog #:
IN0073| IN0073-1g | USD118.0 |
Synonyms: Tamoxifen, Crisafeno, Diemon, Citogen, Istubal, Oncomox, Retaxim, Tamizam, Tamoxen, Valodex, Nolvadex
IUPAC Name:
(Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
Functional Activity:
Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, hence tamoxifen may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine (anti-estrogen) therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. It is also a selective and potent inhibitor of mammalian sterol isomerase. Neuroprotective in female rats in vivo. Also high affinity agonist at the membrane estrogen receptor GPR30.
Some breast cancer cells require estrogen to grow. Estrogen binds to and activates the estrogen receptor in these cells. Tamoxifen is metabolized into compounds that also bind to the estrogen receptor but do not activate it. Because of this competitive antagonism, tamoxifen acts like a key broken off in the lock that prevents any other key from being inserted, preventing estrogen from binding to its receptor. Hence breast cancer cell growth is blocked.
Technical Data:
M.Wt: 371.51
Formula: C26H29NO
.C6H8O7Solubility: Soluble in methanlol and in ethanol
Purity: >99%
Storage: -20°C
CAS No.: 54965-24-1
Related Products by Target:
References for Tamoxifen:
1. Phuong, N. T., Kim, S. K., Lim, S. C., Kim, H. S., Kim, T. H., Lee, K. Y., Ahn, S. G., Yoon, J. H., and Kang, K. W. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat, 130: 73-83.
2. Criscitiello, C., Fumagalli, D., Saini, K. S., and Loi, S. Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. Onco Targets Ther, 4: 1-11.
3. Abo-Touk, N. A., Sakr, H. A., and Abd El-Lattef, A. Switching to letrozole versus continued tamoxifen therapy in treatment of postmenopausal women with early breast cancer. J Egypt Natl Canc Inst, 22: 79-85.
4. Aihara, T., Suemasu, K., Takei, H., Hozumi, Y., Takehara, M., Saito, T., Ohsumi, S., Masuda, N., and Ohashi, Y. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy. Oncology, 79: 376-381.
5. Stendahl, M., Nilsson, S., Wigerup, C., Jirstrom, K., Jonsson, P. E., Stal, O., and Landberg, G. p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients. Int J Cancer, 127: 2851-2858.
6. Gao, L., Tu, Y., Wegman, P., Wingren, S., and Eriksson, L. A. Conformational enantiomerization and estrogen receptor alpha binding of anti-cancer drug tamoxifen and its derivatives. J Chem Inf Model, 51: 306-314.
